Ember Therapeutics, Inc. (EMBT) Stock

About Ember Therapeutics, Inc.

Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.

Ember Therapeutics, Inc. (EMBT) stock trades at $0.00 with a market capitalization of $398. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.02, reflecting a net loss over the last twelve months, price-to-book of 0.00, price-to-sales of 0.00.

On profitability, Ember Therapeutics, Inc. generates a return on equity (ROE) of 10.25% (not meaningful, as shareholders' equity is negative), return on capital employed of 7.31%.

Official website: www.embertx.com